Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 May 2022 | Story Lunga Luthuli
East College - Eco Vehicles Team
Overall winners of the 2022 Eco-vehicle race, East College, hard at work to get their car ready for the race held at the Odeion parking lot on the Bloemfontein Campus.

For the first time, the University of the Free State’s 2022 Eco-vehicle race – held on the Bloemfontein Campus on 14 May 2022 – had students from all three campuses participating in the programme and race; a cup was awarded to the college with the best support.

Although the annual event did take place in 2021, only team members were allowed access to campus due to the COVID-19 pandemic and lockdown regulations, and therefore the race was streamed live. 

Karen Scheepers, Assistant Director: Student Life, said: “To have the students back on campus supporting their teams was incredible; this event will become bigger and better every year.”

With the Eco-vehicle race project, the UFS aims to use an innovative skills development approach that will enable students to develop basic knowledge and skills on sustainable energy.

This year, 130 undergraduate students enrolled for this co-curricular skills programme that runs for nine months and culminates in the Eco-vehicle race. A total of eight teams competed in the energy efficiency race, speed race, obstacle course race, and the main event – the endurance race. For the first time in the main event, the teams raced against each other for 18 laps. 

The winners of this year’s event were Central College (Akasia, Karee, Kagiso, Soetdoring, and Wag-’n-Bietjie residences) for Spirit Cup, South Campus took home the Pit Stop, North College won the Smart Lap, and South College won the Endurance Race. The overall winners of the Eco-vehicle race were East College (Legatum residence). 

The driver for East College, Lebakeng Motlotlo, said: “Even though I have always been part of the KovsieACT Committee in my residence, seeing that the focus this year was more on energy saving and saving resources, it pushed me to participate.”

Motlotlo believes the practice he and his team went through worked for them, as they were able to practise “how to turn, slow down around corners, and save energy”. 

“Our team was very dedicated and knew how to improvise when faced with challenges. As a small residence and most of us living off campus, the race taught us the importance of teamwork.” 

Motlotlo believes “initiatives such as the Eco-vehicle race are important, as we learn other skills outside of lectures, which we sometimes think are not important”.

Scheepers said the plan is to “grow the programme, motivate other universities to also invest in their students through this programme, and race to become a national and maybe an international event”.

“The programme adds value to the student experience to ensure that they do not only obtain a degree during their study period, but also undergo practical application of acquired knowledge and skills through real-life situations and meaningful learning encounters,” said Scheepers. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept